Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsPhase2

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

Sponsor: Gesynta Pharma AB

NCT ID: NCT07260669

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Access to the study treatment being tested
Type of study
Interventional (receives a drug or procedure)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Vipoglanstat (drug), Placebo (drug)
How long the study runs
Study runs about 20 months (dates as stated)
About the drug or intervention
Vipoglanstat — drug: Participants will receive vipoglanstat capsules orally for approximately 4 menstrual cycles during the treatment period. · Placebo — drug: Participants will receive matching placebo capsules orally for approximately 4 menstrual cycles during the treatment period.
Patient visit burden
Not specified by the sponsor
Type of study
Testing a treatment
Ages
18 Years to 44 Years
Who
Female
Number of participants
190
Started
2025-10-15
Last checked
2026-09

Plain English Summary

What is this study?

  • • Testing a new treatment for endometriosis
  • • Phase2 - 190 participants
  • • The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP)

Who can take part?

  • • Ages 18 Years to 44 Years
  • • Diagnosed with endometriosis
  • • Female only

Where?

  • • Bradford - Accellacare Yorkshire
  • • Bristol - Southmead Hospital - North Bristol NHS Trust
  • • Corby - Accellacare Northamptonshire
  • • Coventry - Accellacare Warwickshire
  • • +6 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).

Endometriosis

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years - 44 Years
  • Who can join: Female only

What the study is looking for

  • ✓Premenopausal females 18 to \< 45 years of age at the time of Visit 1.
  • ✓Endometriosis diagnosis confirmed and documented within the last 10 years prior to Visit 1 or during Visit based on:
  • ✓Surgical (via direct visualization or biopsy verified) or
  • ✓Imaging (ie, endometriotic lesion(s) detected by transvaginal sonography or magnetic resonance imaging \[MRI\].
  • ✓History of NMPP significantly affecting daily life confirmed at Visit 1.

Who cannot take part

  • ✗Has had more than 2 surgical procedures for endometriosis.
See the full criteria
Inclusion Criteria: * Premenopausal females 18 to \< 45 years of age at the time of Visit 1. * Endometriosis diagnosis confirmed and documented within the last 10 years prior to Visit 1 or during Visit based on: * Surgical (via direct visualization or biopsy verified) or * Imaging (ie, endometriotic lesion(s) detected by transvaginal sonography or magnetic resonance imaging \[MRI\]. * History of NMPP significantly affecting daily life confirmed at Visit 1. * The participant reports moderate, severe, or very severe pain during non-menstrual days in the month prior to Visit 2, based on patient global assessment NMPP. Exclusion Criteria: * Chronic pelvic pain that is not judged to be primarily related to endometriosis (eg, chronic pelvic infection, interstitial cystitis, nerve entrapments or neuropathies, non-endometriosis-related pelvic adhesive disease, persistent symptomatic ovarian cyst \[eg, dermoid\], posttubal ligation, symptomatic hydrosalpinx, and vaginismus). * Has had more than 2 surgical procedures for endometriosis.

Where Is This Study? (10 UK sites)

Accellacare Yorkshire

Bradford BD18 3SA, United Kingdom

Recruiting

Southmead Hospital - North Bristol NHS Trust

Bristol BS10 5NB, United Kingdom

COMPLETED
Hospital R&D contact (matched)

Helen Lewis-White

Research@nbt.nhs.uk0117 41 49330

Accellacare Northamptonshire

Corby NN18 9EZ, United Kingdom

Recruiting

Accellacare Warwickshire

Coventry CV3 4FJ, United Kingdom

Recruiting

Guy's and St Thomas' NHS Foundation Trust

London SE1 7EH, United Kingdom

Recruiting
Hospital R&D contact (matched)

Main Email: gstt.research.rbhh@nhs.net

gstt.research.rbhh@nhs.netn/a

Accellacare North London

Northwood HA6 2RN, United Kingdom

Recruiting
Hospital R&D contact (matched)

Noclor

contact.noclor@nhs.net020 3317 3034

Norfolk and Norwich University Hospital - Norfolk and Norwich University Hospitals NHS Foundation Trust

Norwich NR4 7UY, United Kingdom

Recruiting
Hospital R&D contact (matched)

Julie Dawson

rdsubmissions@nnuh.nhs.uk01603 286611

Accellacare South London

Orpington BR5 3QG, United Kingdom

Recruiting
Hospital R&D contact (matched)

Dale Batham

slam-ioppn.research@kcl.ac.uk0207 848 0790

University of Oxford

Oxford OX3 9DU, United Kingdom

Recruiting
Hospital R&D contact (matched)

Shahista Hussain

ouhtma@ouh.nhs.uk---

Southampton General Hospital - University Hospital Southampton NHS Foundation Trust

Southampton SO16 6YD, United Kingdom

Recruiting
Hospital R&D contact (matched)

Dr Mikayala King

researchmanagement@uhs.nhs.uk023 81208215

How to Get in Touch

CMO VP Clinical Development

Sponsor contact

CONTACT

+46 762 788 389 ctg@gesynta.se
Data sourced from ClinicalTrials.gov · Last verified: 2026-09